Abstract: Provided herein are methods of detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) and/or other plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of SARS-CoV-2 proteins, such as receptor-binding domain (RBDs) under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the SARS-CoV-2 proteins in the sample to produce bound SARS-CoV-2 proteins. The methods also include detecting the SARS-CoV-2 proteins when aggregations of the bound SARS-CoV-2 proteins form with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.

Abstract: Provided herein are methods of detecting cannabinoid molecules in a sample. The methods include contacting the sample with a plurality of plasmonic metal nanoparticles (MNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first and second epitopes of the cannabinoid molecule under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first and second epitopes of the cannabinoid molecule in the sample to produce bound cannabinoid molecules. The methods also include detecting the cannabinoid molecules when aggregations of MNPs coated with the target cannabinoid molecules form by connecting with one another. Related compositions, reaction mixtures, devices, kits, and systems are also provided.

Abstract: Provided herein are methods of detecting Ebola virus in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) that are conjugated with antibodies, or antigen binding portions thereof, that bind to an epitope of a secreted glycoprotein (sGP) from the Ebola virus under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the epitope of the sGP from the Ebola virus in the sample to produce bound sGP. The methods also include detecting the sGP from the Ebola virus when aggregations of the bound sGP form with one another. Related reaction mixtures, devices, kits, and systems are also provided.

Abstract: The present disclosure provides compositions and methods related to COVID-19 detection. In particular, the present disclosure provides plasmonic metal nanoparticles (MNPs) for use in assays to detect and/or quantify neutralizing antibodies to SARS-CoV-2 in a sample. The compositions and methods of the present disclosure provide a portable, inexpensive, rapid, and accurate antibody assay platform that can be used to evaluate protective immune responses in individuals who have recovered from COVID-19 infection, as well as the efficacy, strength, and duration of vaccines that are under development or in clinical trials.

Abstract: Provided herein are methods of detecting Ebola virus in a sample. The methods include contacting the sample with a plurality of gold nanoparticles (AuNPs) that are conjugated with at least two sets of antibodies, or antigen binding portions thereof, that binds to at least first or second epitopes of glycoproteins, such as secreted glycoproteins (sGPs) from the Ebola virus under conditions sufficient for the antibodies, or the antigen binding portions thereof, to bind to the first or second epitopes of the glycoproteins from the Ebola virus in the sample to produce bound glycoproteins. The methods also include detecting the glycoproteins from the Ebola virus when aggregations of the bound glycoproteins form with one another. Related reaction mixtures, devices, kits, and systems are also provided.